Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years

Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 ye...

Full description

Saved in:
Bibliographic Details
Published in:Liver research 2020-12, Vol.4 (4), p.206-211
Main Authors: Tsuchiya, Kyohei, Ohki, Takamasa, Sato, Koki, Kondo, Mayuko, Toda, Nobuo, Tagawa, Kazumi
Format: Article
Language:English
Subjects:
Elderly patients
Hepatocellular carcinoma (HCC)
Locoregional therapy
Propensity score matching
Radiofrequency ablation (RFA)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3335-2a2fb39ff70d3101dfb567bf1e717eee5d2f268286f3c9712c616083ae5d31f93
cites cdi_FETCH-LOGICAL-c3335-2a2fb39ff70d3101dfb567bf1e717eee5d2f268286f3c9712c616083ae5d31f93
container_end_page 211
container_issue 4
container_start_page 206
container_title Liver research
container_volume 4
creator Tsuchiya, Kyohei
Ohki, Takamasa
Sato, Koki
Kondo, Mayuko
Toda, Nobuo
Tagawa, Kazumi
description Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 years. A total of 512 naïve patients with HCC who had undergone RFA from January 2001 to December 2016 were enrolled. They were categorized into the ≥80-year-old group and the control group (aged
doi_str_mv 10.1016/j.livres.2020.11.005
format article
fullrecord <record><control><sourceid>elsevier_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e2651384fca04552847544a0d2e3687e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2542568420300611</els_id><doaj_id>oai_doaj_org_article_e2651384fca04552847544a0d2e3687e</doaj_id><sourcerecordid>S2542568420300611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3335-2a2fb39ff70d3101dfb567bf1e717eee5d2f268286f3c9712c616083ae5d31f93</originalsourceid><addsrcrecordid>eNp9kUtuGzEMhgdBCjRwc4MudAE7eo-8CRAEzgMI0E27FmgNlcoYjxxKNuAj9CC9WE9SuQ6KrroiwZ_8QPLvus-CLwQX9mazGNOBsCwkl60kFpybi-5KGi3nxjp9-U_-sbsuZcM5F05aa_RVV1cxpgDhyHJkO6SwrzBh3hdGMKQcCd_2ODUZ1iPUlCcWM7HvuIOaA47jfgRiASikKW-BVUKoW5wqSxNrPamlhcErDuzXj5-OsyMClU_dhwhjwev3OOu-Pay-3j_NX748Pt_fvcyDUsrMJci4VssYez6odusQ18b26yiwFz0imkFGaZ10Nqqw7IUMVljuFDRFibhUs-75zB0ybPyO0hbo6DMk_6eQ6dUD1RRG9CitEcrpGIBrY6TTvdEa-CBRWddjY-kzK1AuhTD-5QnuT0b4jT8b4U9GeCF8M6KN3Z7HsN15SEi-hPaUgEMiDLUtkv4P-A2xXpWV</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years</title><source>Elsevier ScienceDirect Journals</source><creator>Tsuchiya, Kyohei ; Ohki, Takamasa ; Sato, Koki ; Kondo, Mayuko ; Toda, Nobuo ; Tagawa, Kazumi</creator><creatorcontrib>Tsuchiya, Kyohei ; Ohki, Takamasa ; Sato, Koki ; Kondo, Mayuko ; Toda, Nobuo ; Tagawa, Kazumi</creatorcontrib><description>Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 years. A total of 512 naïve patients with HCC who had undergone RFA from January 2001 to December 2016 were enrolled. They were categorized into the ≥80-year-old group and the control group (aged &lt;80 years). The primary endpoint was overall survival (OS), and the secondary endpoints were recurrence-free survival, complications associated with RFA, and cause of death. Propensity score matching was performed to adjust for patients’ sex, liver function, tumor number, tumor diameter, and hepatitis C virus infection. Finally, the data of 68 patients in the ≥80-year-old group and 68 in the control group were analyzed; their baseline characteristics, primary endpoint, and secondary endpoints were compared. There were significant differences in the alanine aminotransferase level and prothrombin time between the groups. The cumulative OS rate was not significantly different between the groups (P = 0.83): 98.5%, 87.9%, and 50.5% in the ≥80-year-old group and 94.1%, 72.8%, and 49.3% in the control group at 1, 3, and 5 years, respectively. Age ≥80 years was not significantly associated with OS in multivariate analyses. Liver-related death occurred in 17 patients in the ≥80 year-old group and in 16 patients in the control group (P = 1.00). RFA is safe and effective for the treatment of patients with HCC aged ≥ 80 years.</description><identifier>ISSN: 2542-5684</identifier><identifier>EISSN: 2542-5684</identifier><identifier>DOI: 10.1016/j.livres.2020.11.005</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Elderly patients ; Hepatocellular carcinoma (HCC) ; Locoregional therapy ; Propensity score matching ; Radiofrequency ablation (RFA)</subject><ispartof>Liver research, 2020-12, Vol.4 (4), p.206-211</ispartof><rights>2020 The Third Affiliated Hospital of Sun Yat-sen University</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3335-2a2fb39ff70d3101dfb567bf1e717eee5d2f268286f3c9712c616083ae5d31f93</citedby><cites>FETCH-LOGICAL-c3335-2a2fb39ff70d3101dfb567bf1e717eee5d2f268286f3c9712c616083ae5d31f93</cites><orcidid>0000-0003-1501-3739</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2542568420300611$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45779</link.rule.ids></links><search><creatorcontrib>Tsuchiya, Kyohei</creatorcontrib><creatorcontrib>Ohki, Takamasa</creatorcontrib><creatorcontrib>Sato, Koki</creatorcontrib><creatorcontrib>Kondo, Mayuko</creatorcontrib><creatorcontrib>Toda, Nobuo</creatorcontrib><creatorcontrib>Tagawa, Kazumi</creatorcontrib><title>Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years</title><title>Liver research</title><description>Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 years. A total of 512 naïve patients with HCC who had undergone RFA from January 2001 to December 2016 were enrolled. They were categorized into the ≥80-year-old group and the control group (aged &lt;80 years). The primary endpoint was overall survival (OS), and the secondary endpoints were recurrence-free survival, complications associated with RFA, and cause of death. Propensity score matching was performed to adjust for patients’ sex, liver function, tumor number, tumor diameter, and hepatitis C virus infection. Finally, the data of 68 patients in the ≥80-year-old group and 68 in the control group were analyzed; their baseline characteristics, primary endpoint, and secondary endpoints were compared. There were significant differences in the alanine aminotransferase level and prothrombin time between the groups. The cumulative OS rate was not significantly different between the groups (P = 0.83): 98.5%, 87.9%, and 50.5% in the ≥80-year-old group and 94.1%, 72.8%, and 49.3% in the control group at 1, 3, and 5 years, respectively. Age ≥80 years was not significantly associated with OS in multivariate analyses. Liver-related death occurred in 17 patients in the ≥80 year-old group and in 16 patients in the control group (P = 1.00). RFA is safe and effective for the treatment of patients with HCC aged ≥ 80 years.</description><subject>Elderly patients</subject><subject>Hepatocellular carcinoma (HCC)</subject><subject>Locoregional therapy</subject><subject>Propensity score matching</subject><subject>Radiofrequency ablation (RFA)</subject><issn>2542-5684</issn><issn>2542-5684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kUtuGzEMhgdBCjRwc4MudAE7eo-8CRAEzgMI0E27FmgNlcoYjxxKNuAj9CC9WE9SuQ6KrroiwZ_8QPLvus-CLwQX9mazGNOBsCwkl60kFpybi-5KGi3nxjp9-U_-sbsuZcM5F05aa_RVV1cxpgDhyHJkO6SwrzBh3hdGMKQcCd_2ODUZ1iPUlCcWM7HvuIOaA47jfgRiASikKW-BVUKoW5wqSxNrPamlhcErDuzXj5-OsyMClU_dhwhjwev3OOu-Pay-3j_NX748Pt_fvcyDUsrMJci4VssYez6odusQ18b26yiwFz0imkFGaZ10Nqqw7IUMVljuFDRFibhUs-75zB0ybPyO0hbo6DMk_6eQ6dUD1RRG9CitEcrpGIBrY6TTvdEa-CBRWddjY-kzK1AuhTD-5QnuT0b4jT8b4U9GeCF8M6KN3Z7HsN15SEi-hPaUgEMiDLUtkv4P-A2xXpWV</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Tsuchiya, Kyohei</creator><creator>Ohki, Takamasa</creator><creator>Sato, Koki</creator><creator>Kondo, Mayuko</creator><creator>Toda, Nobuo</creator><creator>Tagawa, Kazumi</creator><general>Elsevier B.V</general><general>KeAi Communications Co., Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1501-3739</orcidid></search><sort><creationdate>202012</creationdate><title>Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years</title><author>Tsuchiya, Kyohei ; Ohki, Takamasa ; Sato, Koki ; Kondo, Mayuko ; Toda, Nobuo ; Tagawa, Kazumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3335-2a2fb39ff70d3101dfb567bf1e717eee5d2f268286f3c9712c616083ae5d31f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Elderly patients</topic><topic>Hepatocellular carcinoma (HCC)</topic><topic>Locoregional therapy</topic><topic>Propensity score matching</topic><topic>Radiofrequency ablation (RFA)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsuchiya, Kyohei</creatorcontrib><creatorcontrib>Ohki, Takamasa</creatorcontrib><creatorcontrib>Sato, Koki</creatorcontrib><creatorcontrib>Kondo, Mayuko</creatorcontrib><creatorcontrib>Toda, Nobuo</creatorcontrib><creatorcontrib>Tagawa, Kazumi</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Liver research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsuchiya, Kyohei</au><au>Ohki, Takamasa</au><au>Sato, Koki</au><au>Kondo, Mayuko</au><au>Toda, Nobuo</au><au>Tagawa, Kazumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years</atitle><jtitle>Liver research</jtitle><date>2020-12</date><risdate>2020</risdate><volume>4</volume><issue>4</issue><spage>206</spage><epage>211</epage><pages>206-211</pages><issn>2542-5684</issn><eissn>2542-5684</eissn><abstract>Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 years. A total of 512 naïve patients with HCC who had undergone RFA from January 2001 to December 2016 were enrolled. They were categorized into the ≥80-year-old group and the control group (aged &lt;80 years). The primary endpoint was overall survival (OS), and the secondary endpoints were recurrence-free survival, complications associated with RFA, and cause of death. Propensity score matching was performed to adjust for patients’ sex, liver function, tumor number, tumor diameter, and hepatitis C virus infection. Finally, the data of 68 patients in the ≥80-year-old group and 68 in the control group were analyzed; their baseline characteristics, primary endpoint, and secondary endpoints were compared. There were significant differences in the alanine aminotransferase level and prothrombin time between the groups. The cumulative OS rate was not significantly different between the groups (P = 0.83): 98.5%, 87.9%, and 50.5% in the ≥80-year-old group and 94.1%, 72.8%, and 49.3% in the control group at 1, 3, and 5 years, respectively. Age ≥80 years was not significantly associated with OS in multivariate analyses. Liver-related death occurred in 17 patients in the ≥80 year-old group and in 16 patients in the control group (P = 1.00). RFA is safe and effective for the treatment of patients with HCC aged ≥ 80 years.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.livres.2020.11.005</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1501-3739</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2542-5684
ispartof Liver research, 2020-12, Vol.4 (4), p.206-211
issn 2542-5684
2542-5684
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e2651384fca04552847544a0d2e3687e
source Elsevier ScienceDirect Journals
subjects Elderly patients
Hepatocellular carcinoma (HCC)
Locoregional therapy
Propensity score matching
Radiofrequency ablation (RFA)
title Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A29%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20percutaneous%20radiofrequency%20ablation%20for%20hepatocellular%20carcinoma%20treatment%20in%20patients%20aged%20%E2%89%A580%20years&rft.jtitle=Liver%20research&rft.au=Tsuchiya,%20Kyohei&rft.date=2020-12&rft.volume=4&rft.issue=4&rft.spage=206&rft.epage=211&rft.pages=206-211&rft.issn=2542-5684&rft.eissn=2542-5684&rft_id=info:doi/10.1016/j.livres.2020.11.005&rft_dat=%3Celsevier_doaj_%3ES2542568420300611%3C/elsevier_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3335-2a2fb39ff70d3101dfb567bf1e717eee5d2f268286f3c9712c616083ae5d31f93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true